Oxford Expression Technologies Ltd. (OET) was established in 2007 from a collaboration between Oxford Brookes University and the Natural Environment Research Council. It provides products, services and consultancy to the global pharmaceutical and biotechnology industries from its base in Oxford, England and has become a world-renowned centre of excellence for Baculovirus protein expression.
OET’s success has been built around its core technology, flashBACTM.
flashBACTM is a one-step, easy-to-use, high throughput Baculovirus-based protein expression platform that enables fast and simultaneous production of multiple recombinant viruses. This technology is suitable for both simple and complex protein expression systems, allowing scientists to produce proteins faster, more easily and more cost-effectively.
OET continues to expand into other areas and applications of both insect and mammalian expression systems in order to broaden its portfolio. In particular, OET has a strong research base in novel applications such as Virus Like Particle production and the BacMam system, and is working in partnership with a number of other organisations to develop these further.
OET is currently engaged in two large grant-funded projects for the development of novel vaccines for Covid-19 and Crimean Congo Haemorrhagic Fever virus.
OET is now established as a world opinion leader and provider of Baculovirus expression products and services, contract research and expertise. Its close working relationship with the pharmaceutical and biotechnology industries globally is ensuring that the need for high quality and cost-effective solutions for gene expression and protein production continues to be met.
